Time flies with great content! Renew in to keep enjoying all our premium content.
Prime
Patent expiry opens door to cheaper Ozempic in Kenya
Ozempic is manufactured by Danish pharmaceutical company Novo Nordisk, which has built an extensive patent portfolio around semaglutide across dozens of countries.
Patients in Kenya, currently paying up to Sh150,000 a month for the diabetes drug Ozempic, could soon access the treatment at a fraction of the cost following the expiry of its patent.
Pharmaceutical manufacturers across India, China and Brazil are already moving to flood global markets with cheaper versions of the drug’s active ingredient.
